Plain-English translation of NCT07009132 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether a liver function test called the HepQuant dual cholate clearance assay can help doctors understand and predict liver problems in people with Fontan procedure or right heart failure. The test measures how quickly your liver processes a special substance, which reflects how well blood is flowing through your liver. Researchers want to see if this test can predict which patients might develop liver complications over time.
People who have had a Fontan procedure or have right heart failure often develop liver problems because blood doesn't flow through their liver as well as it should. Currently, doctors don't have a good test to catch these problems early or predict who will get sicker. This study aims to find out if this new test can help doctors identify and monitor liver disease before it becomes severe.
You likely qualify if…
You likely don't qualify if…
At the start of the study, you will have a liver function test (the HepQuant assay) and a heart MRI scan. After that, the study team will collect information about your health status for 5 years through follow-up appointments and by reviewing your medical records. You won't need to take any experimental medication — the study is focused on testing whether this liver function test works well in your condition and can predict how you'll do over time.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States